REGN Potential key support areaPlease pay close attention to this crucial support level. It previously served as a significant resistance level and also represented a period of market equilibrium and concentration.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
38.8 EUR
3.58 B EUR
11.88 B EUR
105.94 M
About Regeneron Pharmaceuticals, Inc.
Sector
CEO
Leonard S. Schleifer
Headquarters
Tarrytown
Website
Founded
1988
FIGI
BBG00GQ6S8S4
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
REGNabove 1024 heading to 1065
an upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
REGN possible accumulation at a key levelCM Williams Vix Fix postulates the bottom is forming. REGN did have a pull back to key level and could be accumulating. SRSI levels are in good range. RSI levels are forming to acceptable ranges. Let's see if we get a structure on the key level and positive break out.
Head and Shoulders top The target of the head and shoulders top takes the price down to the long term trend line which will act as a key level of resistance. Some 19% fall from today prices
Breakdown of the 200 EMA will cause the price to drop to the next key level of support and this is about 18-19% lower
REGN should continue rally in bullish daily sequenceREGN favors upside as long as it stays above price trendline as the part of iii started from October-2023 low and expect few more highs before pullback in iv correction.
REGN potential Buy setupReasons for bullish bias:
- Simple DOW theory
- Entry at HH breakout
- No divergence
Here are the recommended trading levels:
Entry Level(CMP): 1000.64
Stop Loss Level: 949.00
Take Profit Level 1: 1052.28
Take Profit Level 2: 1103.92
Take Profit Level 3: Open
regn has been a monster in the making and setting new highsAs we are still in an uptrend, no reversal decision or reversal change in technical analysis. I am interested to see it go up and continue this rise to higher highs, and until we see sudden change in reversal, I will continue to ride the gravy train, up the streets of san fran!!!
Going Long on Regeneron (REGN)Regeneron Pharmaceuticals (REGN) is a stock that has seen an appreciation in its stock price since the beginning of the year. This trading idea focuses on the company's financial performance and its potential for future growth.
Key Metrics:
Gross Profit Ratio: Regeneron's gross profit ratio cu
$REGN with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:REGN after a negative under reaction following its earnings release placing the stock in drift D .
#regn buy signal @regn buy position @742.2$
Good financial ratios and good indicators level
@intelligent.investing.144
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
7.12%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.53%
Maturity date
Sep 15, 2030
Explore more bonds
Curated watchlists where REGN is featured.
Frequently Asked Questions
The current price of REGN is 711.8 EUR — it has increased by 0.03% in the past 24 hours. Watch REGENERON PHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange REGENERON PHARMACEUTICALS stocks are traded under the ticker REGN.
REGN stock has fallen by −7.29% compared to the previous week, the month change is a −20.97% fall, over the last year REGENERON PHARMACEUTICALS has showed a −2.63% decrease.
We've gathered analysts' opinions on REGENERON PHARMACEUTICALS future price: according to them, REGN price has a max estimate of 1,167.05 EUR and a min estimate of 759.06 EUR. Watch REGN chart and read a more detailed REGENERON PHARMACEUTICALS stock forecast: see what analysts think of REGENERON PHARMACEUTICALS and suggest that you do with its stocks.
REGN reached its all-time high on Aug 29, 2024 with the price of 1,091.6 EUR, and its all-time low was 238.6 EUR and was reached on May 9, 2018. View more price dynamics on REGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
REGN stock is 0.82% volatile and has beta coefficient of 0.79. Track REGENERON PHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is REGENERON PHARMACEUTICALS there?
Today REGENERON PHARMACEUTICALS has the market capitalization of 77.48 B, it has decreased by −5.13% over the last week.
Yes, you can track REGENERON PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
REGENERON PHARMACEUTICALS is going to release the next earnings report on Jan 31, 2025. Keep track of upcoming events with our Earnings Calendar.
REGN earnings for the last quarter are 11.19 EUR per share, whereas the estimation was 10.50 EUR resulting in a 6.54% surprise. The estimated earnings for the next quarter are 10.52 EUR per share. See more details about REGENERON PHARMACEUTICALS earnings.
REGENERON PHARMACEUTICALS revenue for the last quarter amounts to 3.34 B EUR, despite the estimated figure of 3.30 B EUR. In the next quarter, revenue is expected to reach 3.56 B EUR.
REGN net income for the last quarter is 1.20 B EUR, while the quarter before that showed 1.34 B EUR of net income which accounts for −9.96% change. Track more REGENERON PHARMACEUTICALS financial stats to get the full picture.
No, REGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 13.45 K employees. See our rating of the largest employees — is REGENERON PHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENERON PHARMACEUTICALS EBITDA is 4.14 B EUR, and current EBITDA margin is 36.36%. See more stats in REGENERON PHARMACEUTICALS financial statements.
Like other stocks, REGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENERON PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENERON PHARMACEUTICALS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENERON PHARMACEUTICALS stock shows the sell signal. See more of REGENERON PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.